-
Je něco špatně v tomto záznamu ?
Young (<35 years) haploidentical versus old (≥35 years) mismatched unrelated donors and vice versa for allogeneic stem cell transplantation with post-transplant cyclophosphamide in patients with acute myeloid leukemia in first remission: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
A. Nagler, M. Labopin, R. Swoboda, D. Blaise, E. Angelucci, J. Vydra, LL. Corral, S. Bramanti, P. Chiusolo, M. Kwon, Y. Koc, M. Itäla-Remes, M. Martino, A. Kulagin, A. Busca, F. Ciceri, M. Mohty
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, srovnávací studie
NLK
Free Medical Journals
od 1997 do Před 1 rokem
Freely Accessible Science Journals
od 1997 do Před 1 rokem
ProQuest Central
od 2000-01-01 do Před 1 rokem
Open Access Digital Library
od 1997-01-01
Health & Medicine (ProQuest)
od 2000-01-01 do Před 1 rokem
- MeSH
- akutní myeloidní leukemie * terapie mortalita MeSH
- cyklofosfamid * terapeutické užití MeSH
- dítě MeSH
- dospělí MeSH
- haploidentická transplantace metody MeSH
- homologní transplantace metody MeSH
- indukce remise MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- nemoc štěpu proti hostiteli MeSH
- nepříbuzný dárce * MeSH
- přežití bez známek nemoci MeSH
- příprava pacienta k transplantaci metody MeSH
- transplantace hematopoetických kmenových buněk * metody MeSH
- věkové faktory MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- srovnávací studie MeSH
- Geografické názvy
- Evropa MeSH
We compared transplantation (HSCT) outcomes in AML patients undergoing HSCT with post-transplant cyclophosphamide (PTCy) in first complete remission from 1065 young (<35 years) haploidentical (Haplo) donors (yHaplo) vs. 147 old (≥35 years) mismatched unrelated donors (oMMUD) (first comparison) and from 271 young (<35 years) MMUD (yMMUD) vs. 1315 old (≥35 years) Haplo donors (oHaplo) (second comparison). Acute graft-versus-host disease (aGVHD) grades II-IV were significantly lower in the yHaplo vs. oMMUD group (HR = 0.62, p = 0.007). There were no significant differences in chronic GVHD, non-relapse mortality (NRM), relapse incidence, leukemia-free survival, overall survival, and GVHD-free and relapse-free survival. As for the second comparison, more patients in the oHaplo group had de novo AML, 86.6% vs. 81.9% in the yMMUD group (p = 0.044), while myeloablative conditioning was used more frequently in the yMMUD group, 53.3% vs. 46.8% in the oHaplo group (p = 0.049). aGVHD grades II-IV and NRM were significantly lower in the yMMUD vs. oHaplo group (HR = 0.69, p = 0.013 and HR = 0.60, p = 0.022). All other transplant outcomes did not differ. In conclusion, HSCT from young alternative donors (<35 years) results in a lower incidence of grades II-IV aGVHD. In addition, NRM is lower in HSCT from yMMUD compared to HSCT from oHaplo.
Department of Hematology Saint Antoine Hospital INSERM UMR 938 Sorbonne University Paris France
Division of Hematology Sheba Medical Center Tel Hashomer Israel
Hospital Clínico Salamanca Spain
Institute of Hematology and Blood Transfusion Prague Czech Republic
IRCCS Osspedale San Raffaele Vita Salute San Raffaele University Hematology and BMT Milano Italy
Maria Sklodowska Curie National Research Institute of Oncology Gliwice Branch Gliwice Poland
Medicana International Hospital Istanbul Istanbul Turkey
Ospedale San Raffaele s r l Milano Italy
Programme de Transplantation and Therapie Cellulaire Marseille France
RM Gorbacheva Research Institute Pavlov University Petersburg Russian Federation
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25003699
- 003
- CZ-PrNML
- 005
- 20250206104625.0
- 007
- ta
- 008
- 250121s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41409-024-02400-5 $2 doi
- 035 __
- $a (PubMed)39155338
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Nagler, Arnon $u Division of Hematology, Sheba Medical Center, Tel Hashomer, Israel. arnon.nagler@sheba.health.gov.il $1 https://orcid.org/0000000207631265
- 245 10
- $a Young (<35 years) haploidentical versus old (≥35 years) mismatched unrelated donors and vice versa for allogeneic stem cell transplantation with post-transplant cyclophosphamide in patients with acute myeloid leukemia in first remission: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation / $c A. Nagler, M. Labopin, R. Swoboda, D. Blaise, E. Angelucci, J. Vydra, LL. Corral, S. Bramanti, P. Chiusolo, M. Kwon, Y. Koc, M. Itäla-Remes, M. Martino, A. Kulagin, A. Busca, F. Ciceri, M. Mohty
- 520 9_
- $a We compared transplantation (HSCT) outcomes in AML patients undergoing HSCT with post-transplant cyclophosphamide (PTCy) in first complete remission from 1065 young (<35 years) haploidentical (Haplo) donors (yHaplo) vs. 147 old (≥35 years) mismatched unrelated donors (oMMUD) (first comparison) and from 271 young (<35 years) MMUD (yMMUD) vs. 1315 old (≥35 years) Haplo donors (oHaplo) (second comparison). Acute graft-versus-host disease (aGVHD) grades II-IV were significantly lower in the yHaplo vs. oMMUD group (HR = 0.62, p = 0.007). There were no significant differences in chronic GVHD, non-relapse mortality (NRM), relapse incidence, leukemia-free survival, overall survival, and GVHD-free and relapse-free survival. As for the second comparison, more patients in the oHaplo group had de novo AML, 86.6% vs. 81.9% in the yMMUD group (p = 0.044), while myeloablative conditioning was used more frequently in the yMMUD group, 53.3% vs. 46.8% in the oHaplo group (p = 0.049). aGVHD grades II-IV and NRM were significantly lower in the yMMUD vs. oHaplo group (HR = 0.69, p = 0.013 and HR = 0.60, p = 0.022). All other transplant outcomes did not differ. In conclusion, HSCT from young alternative donors (<35 years) results in a lower incidence of grades II-IV aGVHD. In addition, NRM is lower in HSCT from yMMUD compared to HSCT from oHaplo.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a cyklofosfamid $x terapeutické užití $7 D003520
- 650 _2
- $a dospělí $7 D000328
- 650 12
- $a akutní myeloidní leukemie $x terapie $x mortalita $7 D015470
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a nepříbuzný dárce $7 D061349
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a transplantace hematopoetických kmenových buněk $x metody $7 D018380
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a mladý dospělý $7 D055815
- 650 _2
- $a nemoc štěpu proti hostiteli $7 D006086
- 650 _2
- $a haploidentická transplantace $x metody $7 D000075442
- 650 _2
- $a indukce remise $7 D012074
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 _2
- $a věkové faktory $7 D000367
- 650 _2
- $a příprava pacienta k transplantaci $x metody $7 D019172
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a homologní transplantace $x metody $7 D014184
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a srovnávací studie $7 D003160
- 700 1_
- $a Labopin, Myriam $u Department of Hematology, EBMT Paris Study Office, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France $u Department of Hematology, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France
- 700 1_
- $a Swoboda, Ryszard $u Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland $1 https://orcid.org/0000000258973919
- 700 1_
- $a Blaise, Didier $u Programme de Transplantation & Therapie Cellulaire, Marseille, France
- 700 1_
- $a Angelucci, Emanuele $u Ospedale San Raffaele s.r.l., Milano, Italy
- 700 1_
- $a Vydra, Jan $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $1 https://orcid.org/0000000242743895
- 700 1_
- $a Corral, Lucía López $u Hospital Clínico, Salamanca, Spain $1 https://orcid.org/0000000319085596
- 700 1_
- $a Bramanti, Stefania $u Transplantation Unit Department of Oncology and Haematology, IRCCS Humanitas Research Hospital, Milan, Italy $1 https://orcid.org/0000000241177991
- 700 1_
- $a Chiusolo, Patrizia $u Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica Sacro Cuore, Rome, Italy $1 https://orcid.org/0000000213551587
- 700 1_
- $a Kwon, Mi $u Department of Hematology, Hospital General Universitario Gregorio Marañon, Institute of Health Research Gregorio Marañon, Madrid, Spain
- 700 1_
- $a Koc, Yener $u Medicana International Hospital Istanbul, Istanbul, Turkey
- 700 1_
- $a Itäla-Remes, Maija $u Turku University Hospital, Turku, Finland
- 700 1_
- $a Martino, Massimo $u Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy $1 https://orcid.org/000000023987419X
- 700 1_
- $a Kulagin, Alexander $u RM Gorbacheva Research Institute, Pavlov University, Petersburg, Russian Federation
- 700 1_
- $a Busca, Alessandro $u S.S.C.V. D Trapianto di Cellule Staminali, Torino, Italy $1 https://orcid.org/0000000153615613
- 700 1_
- $a Ciceri, Fabio $u IRCCS Osspedale San Raffaele, Vita-Salute San Raffaele University Hematology and BMT, Milano, Italy $1 https://orcid.org/0000000308730123
- 700 1_
- $a Mohty, Mohamad $u Department of Hematology, EBMT Paris Study Office, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France $u Department of Hematology, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France $1 https://orcid.org/000000027264808X $7 xx0317729
- 773 0_
- $w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 59, č. 11 (2024), s. 1552-1562
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39155338 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206104621 $b ABA008
- 999 __
- $a ok $b bmc $g 2263454 $s 1239706
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 59 $c 11 $d 1552-1562 $e 20240818 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
- LZP __
- $a Pubmed-20250121
